Interchange Capital Partners LLC Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Interchange Capital Partners LLC purchased a new position in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, Holdings Channel reports. The fund purchased 1,787 shares of the company’s stock, valued at approximately $212,000.

Other institutional investors also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna in the fourth quarter worth approximately $27,000. Family Firm Inc. acquired a new stake in Moderna during the second quarter worth approximately $33,000. Cedar Wealth Management LLC raised its holdings in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. acquired a new stake in Moderna during the first quarter worth approximately $32,000. Finally, Bank & Trust Co acquired a new stake in Moderna during the second quarter worth approximately $36,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $157.00 price objective (down previously from $214.00) on shares of Moderna in a report on Friday, August 2nd. Evercore ISI reaffirmed an “in-line” rating and issued a $120.00 target price on shares of Moderna in a report on Thursday, June 27th. Barclays cut their target price on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a report on Friday, August 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, August 1st. Finally, UBS Group boosted their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Ten equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $123.79.

Moderna Price Performance

Moderna stock opened at $77.40 on Monday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $104.62 and its 200 day simple moving average is $113.18. The firm has a market capitalization of $29.75 billion, a PE ratio of -4.94 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the firm earned ($3.62) EPS. The business’s revenue for the quarter was down 29.9% compared to the same quarter last year. On average, equities research analysts predict that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $151.25, for a total value of $2,268,750.00. Following the transaction, the director now directly owns 1,946,931 shares in the company, valued at approximately $294,473,313.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $151.25, for a total transaction of $2,268,750.00. Following the completion of the transaction, the director now owns 1,946,931 shares in the company, valued at $294,473,313.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 330,736 shares of company stock worth $46,330,112. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.